Qorvo’s sensor-based technology immunoassay platform selected by expert committee for development grant. The Foundation for Innovative New Diagnostics (FIND) announced awards to support the development, manufacture and feasibility testing for two prototype hepatitis C virus (HCV) core antigen (cAg) immunoassays for diagnosis at point-of-care. Zomedica’s latest diagnostic collaborator, Qorvo Biotechnologies, LLC (Qorvo) is one of the companies to receive support …
Click on Detroit, Tech Time with Andrew Humprey: Liquid biopsy is the new way to help diagnose and cure cancer for pets
July 9, 2018 Zomedica, an Ann Arbor pharmaceutical company, is trying to cure cancer in pets more easily with a new procedure called liquid biopsy. LEARN MORE>>
Zomedica discusses the need for pet cancer diagnostics in the latest Investor Chat podcast from Stockhouse
March 19, 2018 In many respects, animal health is an under-served field. Many of the medications used to treat animal health disorders are actually human drugs, developed for human physiology, and compounded drugs that have not been proven safe or effective for animal use. As Zomedica began advancing its pipeline of pet pharmaceutical products, the company’s attention was drawn to …
Winners of Zomedica-Sponsored Veterinary Innovation Awards Announced by NAVC and The Veterinary Innovation Council
February 4, 2018 The North American Veterinary Community (NAVC) and the Veterinary Innovation Council (VIC) are excited to announce the winners of their first ever Veterinary Innovation Awards. Sponsored by Zomedica (NYSE American:ZOM) (TSX-V:ZOM), these awards showcase the passionate innovators and organizations that have dedicated themselves to the betterment of the animal health industry. LEARN MORE>>
Stockhouse’s Investor Chat Podcast talks animal health with Zomedica Leadership
Healthcare is a growth industry with respect to human health, but it’s a mature industry where large cap companies control most of the sector. In contrast, animal health is an emerging growth sector in the healthcare space, offering a level of blue-sky potential not available in human healthcare. The pet-pharma market alone is a $10 billion a year market. In …